712 completed, 238 unknown, 151 recruiting, 150 terminated. 879 Phase 2, 335 Phase 3, 326 Phase 1, 51 Not applicable, 22 Phase 4.
Follow this drug Literature Review of Etoposide trials Research Report on Etoposide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1/2 Study Of PARP Inhibition With Olaparib To Enhance The Efficacy Of High-Dose Chemotherapy In Refractory And Relapsed Germ Cell Tumors Olaparib, Gemcitabine, Docetaxel - Germ Cell Cancer | Phase 1 / Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 36 | 2027-03-01 | 2026-10-01 |
| Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC Durvalumab 50 MG/1 ML Intravenous Solution, Etoposide Injection, Cisplatin - Extensive-stage Small-cell Lung Cancer | Phase 1 | Suspended | University of Maryland, Baltimore | 50 | 2027-01-30 | 2026-09-14 |
| A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer ZL-1310 in combination with Atezolizumab or Durvalumab, Carboplatin/Etoposide in Combination with Atezolizumab followed by maintenance Atezolizumab with Lurbinectedin, Carboplatin/Etoposide or Cistplatin/Etoposide in Combination with Durvalumab induction followed by Durvalumab maintenance - Extensive-Stage Small Cell Lung Cancer | Phase 3 | Not yet recruiting | Zai Lab (Shanghai) Co., Ltd. | 530 | 2026-12-31 | 2026-08-31 |
| A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC LBL-024 for Injection, Etoposide injection, Cisplatin injection - Advanced Extrapulmonary Neuroendocrine Carcinoma | Phase 3 | Not yet recruiting | Nanjing Leads Biolabs Co.,Ltd | 280 | 2026-11-16 | 2026-10-19 |
| Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases Immunotherapy, Chemotherapy (Etoposide, Nab-paclitaxel, Irinotecan, or Lurbinectedin), low-dose radiation - Lung Cancer (SCLC) | Phase 2 | Not yet recruiting | Sichuan University | 30 | 2026-10-31 | 2026-05-05 |
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 271 | 2026-10-30 | 2026-08-19 |
| A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity Belinostat, Cisplatin, Etoposide - Carcinoma, Neuroendocrine, Tumor, Neuroendocrine | Phase 2 | Recruiting | National Cancer Institute (NCI) | 60 | 2026-10-26 | 2026-10-21 |
| A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer QLC5508, QL2107, Tislelizumab - Extensive-stage Small Cell Lung Cancer | Phase 3 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 556 | 2026-10-15 | 2026-09-03 |
| ZG005 Plus Etoposide and Cisplatin vs. Etoposide and Cisplatin as First-Line Treatment for Advanced Neuroendocrine Carcinoma ZG005 for Injection, Etoposide Injection, Cisplatin Injection - Neuroendocrine Carcinomas (NEC) | Phase 3 | Not yet recruiting | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 440 | 2026-10-01 | 2026-09-22 |
| A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35) Obrixtamig, Pumitamig, Carboplatin - Extensive-stage Small Cell Lung Carcinoma, Advanced Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Boehringer Ingelheim | 55 | 2026-10-01 | 2026-10-13 |
| Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Adult Burkitt Lymphoma | Phase 2 | Not yet recruiting | AIDS Malignancy Consortium | 43 | 2026-09-17 | 2026-10-16 |
| GELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell Lymphoma Gemcitabine (GEM), Etoposide Injection, Dexamethasone - Natural Killer/T-cell Lymphoma | Phase 2 | Not yet recruiting | Fudan University | 620 | 2026-09-01 | 2026-08-17 |
| A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer YL201, Serplulimab, Carboplatin - SCLC, Extensive Stage | Phase 3 | Recruiting | MediLink Therapeutics (Suzhou) Co., Ltd. | 442 | 2026-08-18 | 2026-08-24 |
| BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01) BL-M14D1 and Atezolizumab, Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin - Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer | Phase 3 | Recruiting | SystImmune Inc. | 550 | 2026-08-04 | 2026-10-15 |
| Toripalimab Combined With Beat Chemotherapy in the Treatment of Advanced Back-line Small Cell Lung Cancer Toripalimab; Etoposide - SCLC, Extensive Stage, Bayesian | Phase 2 | Not yet recruiting | Henan Cancer Hospital | 130 | 2026-08-01 | 2026-07-13 |
| A Single-arm, Exploratory Clinical Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Anlotinib and Etoposide as First-line Therapy for Elderly Patients With Small-cell Lung Cancer or Those Who Are Intolerant to Intensive Chemotherapy benmelstobart in combination with anlotinib and etoposide - Small Cell Lung Cancer ( SCLC ) | Phase 3 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 64 | 2026-08-01 | 2026-07-27 |
| Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung Cancer Etoposide, Cisplatin, Carboplatin - Lung, Radiotherapy | Phase 2 | Recruiting | Jiangmen Central Hospital | 43 | 2026-07-20 | 2026-09-22 |
| DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy Obrixtamig, Carboplatin, Etoposide - Extrapulmonary Neuroendocrine Cancer (epNEC) | Phase 3 | Recruiting | Boehringer Ingelheim | 390 | 2026-07-10 | 2026-10-13 |
| A Phase III, Randomized, Double-blind, Multi-center Trial Comparing Efficacy and Safety of Trilaciclib Versus Placebo in Participants With Limited-stage Small Cell Lung Cancer Trilaciclib, Trilaciclib Placebo, Etoposide Injection - Myelosuppression | Phase 3 | Active not recruiting | Jiangsu Simcere Pharmaceutical Co., Ltd. | 106 | 2026-06-17 | 2026-10-19 |
| A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07) BL-B01D1, Tislelizumab, Carboplatin - Extensive-stage Small-cell Lung Cancer | Phase 3 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 562 | 2026-06-15 | 2026-07-27 |
Showing 20 of 1458. Sign in to see all of them.
Lymphoma (225) · Small Cell Lung Carcinoma (161) · Lymphoma, Large B-Cell, Diffuse (160) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (143) · Lymphoma, Non-Hodgkin (140) · Leukemia (135) · Leukemia, Myeloid, Acute (117) · Hodgkin Disease (106) · Burkitt Lymphoma (101) · Lung Neoplasms (99) · Lymphoma, Follicular (85) · Lymphoma, Mantle-Cell (76) · Lymphoma, Large-Cell, Immunoblastic (68) · Carcinoma, Non-Small-Cell Lung (61) · Neuroblastoma (60)
National Cancer Institute (NCI) (96) · Children's Oncology Group (79) · M.D. Anderson Cancer Center (43) · St. Jude Children's Research Hospital (43) · Memorial Sloan Kettering Cancer Center (42) · City of Hope Medical Center (29) · Alliance for Clinical Trials in Oncology (21) · SWOG Cancer Research Network (20) · Fred Hutchinson Cancer Center (19) · European Organisation for Research and Treatment of Cancer - EORTC (18) · University of Washington (16) · Case Comprehensive Cancer Center (14) · Dana-Farber Cancer Institute (14) · Samsung Medical Center (14) · Sun Yat-sen University (14)
United States (858) · China (230) · Canada (166) · Australia (137) · France (125) · Germany (114) · Italy (109) · United Kingdom (107) · Spain (97) · Netherlands (77) · Switzerland (77) · South Korea (72) · Belgium (70) · Puerto Rico (59) · New Zealand (58)
Craig Moskowitz, MD (8) · Sima Jeha, MD (7) · Ajay Gopal (6) · Julie M Vose, MD (5) · Lode J. Swinnen, MD (5) · Sandra J. Horning, MD (5) · Alex F Herrera (4) · Daniel J. Weisdorf, MD (4) · Jonathan L. Finlay, MB, ChB (4) · Leona Holmberg (4)
PMID 40135712, PMID 33242441, PMID 37505794, PMID 39113428, PMID 29567784, PMID 33357481, PMID 36184621, PMID 36815378, PMID 38295280, PMID 40501401, PMID 42085603, PMID 22551107, PMID 22689675, PMID 31401903, PMID 34515338, PMID 35882475, PMID 36184192, PMID 37267439, PMID 39121442, PMID 15812540, PMID 16105981, PMID 16421426, PMID 19144982, PMID 19433688, PMID 19602710, PMID 20154213, PMID 20567002, PMID 20661232, PMID 21195303, PMID 21343560, PMID 21719599, PMID 22442346, PMID 22493293, PMID 22965967, PMID 24224624, PMID 24344215, PMID 25753432, PMID 26888258, PMID 26913693, PMID 27561722, PMID 28751559, PMID 29148893, PMID 29926156, PMID 30125215, PMID 30523055, PMID 31188727, PMID 31375516, PMID 31545689, PMID 31601692, PMID 31612640
U10CA098543 (42), U10CA180886 (36), U10CA032102 (24), U10CA031946 (21), P30CA033572 (17), P30CA015704 (15), P30CA043703 (13), P30CA016672 (12), 2023 (11), 2016 (9), 2019 (9), U10CA021115 (8), U10CA180821 (8), P30CA036727 (7), U10CA180820 (7)